Settlements

The on-going metal hip litigation varies significantly between the various manufacturers. We make it a priority of ours to help inform you of current settlements and provide you with the information and resources you need to effectively evaluate your options.

Stryker

On November 3rd, 2014, Stryker Orthopedics, a subsidiary of Stryker Corporation, announced it had agreed to a proposed settlement with patients in the United States who had received a Rejuvenate or ABG II implant and had undergone revision surgery to remove the defective device by November 3, 2014.

The settlement, which will exceed $1 billion, will offer a base amount of $300,000 to each qualifying claimant. This amount is subject to enhancements or reductions that will be determined by factors, including age, prior hip revisions, severity of complications and when the complications began.

There are critical deadlines that need to be met in order to preserve your claim. We encourage you to contact our office so we can discuss these deadlines and help you evaluate your options.

For more information about the Stryker litigation and settlement:

Biomet

In February 2014, Biomet, Inc. agreed to a settlement of $56 million for hundreds of lawsuits that were filed in the multi-district litigation in the Northern District of Indiana. The base award for each claimant was $200,000.

This Biomet settlement round required that cases be filed on or before April 15, 2014.

Even though, Biomet has yet to address future settlement rounds, we encourage you to contact our office if you’ve suffered injuries or have had to undergo revision surgery due to a defective Biomet hip replacement.

For more information about the Biomet litigation and settlement:

DePuy

News Update (2.23.15): DePuy Agrees to Extend Current U.S. Settlement Program

In November 2013, DePuy Orthopedics, a Johnson & Johnson subsidiary, reached a settlement agreement with thousands of claimants who had received an ASR hip implant. The agreement was to compensate patients in the United States that had to undergo revision surgery to replace their defective hip replacement prior to August 31, 2013.

The base award for each claimant was $250,000. The settlement was based on an estimated 8,000 participants, with an approximate overall total of $2.5 billion.

In October 2014, it was reported that Johnson & Johnson may pay another $250 million to settle an additional 1,000 ASR hip claims. While this hasn’t been officially confirmed by Johnson & Johnson, we encourage you to contact our firm if you’ve suffered injuries or have had to undergo revision surgery to remove a defective DePuy ASR hip replacement.

For more information about the DePuy litigation and settlement: